<p>(A) EBNA2-specific responses. Top left panel: In vitro expanded, CD8-enriched polyclonal T cells from Donor 17 were screened against overlapping 20mer peptides spanning the complete unique sequence of EBNA2 (sub-divided into 18 pools). T cell recognition was assessed by IFNγ production, measured in an ELISA. Results are expressed as the mean IFNγ concentration +/- SD for duplicate wells. Top right panel: Individual component peptides from pool 6 were screened for their ability to mediate IFNγ production by the CD8-enriched T cell population. Middle panel: To identify the HLA restriction, LCLs sharing one or more class I alleles with Donor 17 (class I type in bold) were pre-loaded with peptides 6.4/6.5 (1μg/ml) and co-cultured overnight w...
<p><b>A</b>. Sequences of the peptides used to identify the immunogenic nonamer epitope in NS4b. IC<...
<p>MoDCs from HLA-A*0201 individuals were transduced with either the non-ubiquitinated (MART 0x, hat...
<p>Healthy donors (HD) #8 and #9 were chosen as representative for donors with different amplitude o...
<p>PBMCs were screened by <i>ex vivo</i> ELISpot analysis for recognition of 187 overlapping 15mer p...
<p>The CD8<sup>+</sup> T cell from donor 1 pre-sensitized with nonamer aa129–aa137 (A), donor 2 pre-...
<p>(A, B) CD8+ T cell clones specific for epitopes from EBV latent antigens (A) or EBV lytic-cycle a...
<p>(A) Peptide-specific T cells in PBMCs from four healthy HLA-B*08:01-positive donors (a-d) were de...
<p>(A) IFN-γ spots, each representing a CD8 T cell responding with IFN-γ production, formed upon sen...
<p>ELISpot analysis (upper row) of a negative responder (HLA-A2<sup>−</sup> recovered individual) (A...
(A) The expansion of gp350- and EBNA1-specific T cells using VLPs/LPs-EBNA1RI+RII and AgAb. PBMCs fr...
<p>A) D432 A5, D432 D2, D432 E7, D432 E8, D432 H8 and D432 A11 T cells (5000 cells of each clone/wel...
<p>Panels, A and B: 293kbC2 cells expressing EBNA1-SIIN-GFP encoding either alternative repeat pepti...
<p>(A) In blue wildtype peptide recognition, in red mutated peptide recognition at first and second ...
(A) Epitope-rich regions from EBNA1 were utilized to construct modified VLPs/LPs. EBNA1 has a single...
<p>PBMCs were initially screened by <i>ex vivo</i> ELISpot and the CD4<sup>+</sup> and CD8<sup>+</su...
<p><b>A</b>. Sequences of the peptides used to identify the immunogenic nonamer epitope in NS4b. IC<...
<p>MoDCs from HLA-A*0201 individuals were transduced with either the non-ubiquitinated (MART 0x, hat...
<p>Healthy donors (HD) #8 and #9 were chosen as representative for donors with different amplitude o...
<p>PBMCs were screened by <i>ex vivo</i> ELISpot analysis for recognition of 187 overlapping 15mer p...
<p>The CD8<sup>+</sup> T cell from donor 1 pre-sensitized with nonamer aa129–aa137 (A), donor 2 pre-...
<p>(A, B) CD8+ T cell clones specific for epitopes from EBV latent antigens (A) or EBV lytic-cycle a...
<p>(A) Peptide-specific T cells in PBMCs from four healthy HLA-B*08:01-positive donors (a-d) were de...
<p>(A) IFN-γ spots, each representing a CD8 T cell responding with IFN-γ production, formed upon sen...
<p>ELISpot analysis (upper row) of a negative responder (HLA-A2<sup>−</sup> recovered individual) (A...
(A) The expansion of gp350- and EBNA1-specific T cells using VLPs/LPs-EBNA1RI+RII and AgAb. PBMCs fr...
<p>A) D432 A5, D432 D2, D432 E7, D432 E8, D432 H8 and D432 A11 T cells (5000 cells of each clone/wel...
<p>Panels, A and B: 293kbC2 cells expressing EBNA1-SIIN-GFP encoding either alternative repeat pepti...
<p>(A) In blue wildtype peptide recognition, in red mutated peptide recognition at first and second ...
(A) Epitope-rich regions from EBNA1 were utilized to construct modified VLPs/LPs. EBNA1 has a single...
<p>PBMCs were initially screened by <i>ex vivo</i> ELISpot and the CD4<sup>+</sup> and CD8<sup>+</su...
<p><b>A</b>. Sequences of the peptides used to identify the immunogenic nonamer epitope in NS4b. IC<...
<p>MoDCs from HLA-A*0201 individuals were transduced with either the non-ubiquitinated (MART 0x, hat...
<p>Healthy donors (HD) #8 and #9 were chosen as representative for donors with different amplitude o...